Graduate School of Dental Medicine, Hokkaido University.

Vascular Biology and Molecular Pathology

Achievements

2014

English-language papers(※corresponding author)

  1. Kibria G., Hatakeyama H.,Akiyama K., Hida K. and *Harashima H.: Comparative Study of the Sensitivities of Cancer Cells to Doxorubicin, and Relationships between the Effect of the Drug-Efflux Pump P-gp, Biol. Pharm. Bull, 37(12), 1926–1935, 2014
  2. Akhter A., Hayashi Y., Sakurai Y., Ohga N., Hida K., *Harashima H.: Ligand density at the surface of a nanoparticle and different uptake mechanism: Two important factors for successful siRNA delivery to liver endothelial cells, Int J Pharm, 475 (1-2):227-237, 2014
  3. Ohmura-Kakutani H., Akiyama K., Maishi N., Ohga N., Hida Y., Kawamoto T., Iida J., Shindoh M., Tsuchiya K., Shinohara N., *Hida K.：Identification of Tumor Endothelial Cells with High Aldehyde Dehydrogenase Activity and a Highly Angiogenic Phenotype,PLoS ONE,  9(12):e113910, 2014
  4. Ara MN., Matsuda T., Hyodo M, Sakurai Y, Ohga N., Hida K.：Construction of an aptamer modified liposomal system targeted to tumor endothelial cells, Bio Pharm Bull, 37(11):1742-9, 2014
  5. Alam MT， Nagao-Kitamoto H., Ohga N., Akiyama K., Maishi N.,  Kawamoto T., Shinohara N., Taketomi A., Shindoh M., Hida Y. and *Hida K.：Suprabasin as a novel tumor endothelial cell marker, Cancer Sci, 105(12), 1533–1540, 2014
  6. Ara MN., Matsuda T., Hyodo M, Sakurai .Y, Hatakeyama H., Ohga N., Hida K., Harashima H. ：An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells，Biomaterials, 35(25), 7110-7120, 2014
  7. Ara MN., Hyodo M., Ohga N., Akiyama K., Hida K., Hida Y., Shinohara N., Harashima H.：Identification and expression of troponin T, a new marker on the surface of cultured tumor endothelial cells by aptamer ligand, Cancer Med, 3(4), 825-834, 2014
  8. Otsubo T., Hida Y., Ohga N., Sato H., Kai T., Matsuki Y., Takasu H., Akiyama K., Maishi N., Kawamoto T., Shinohara N., Nonomura K., *Hida K.：Identification of Novel Targets for Antiangiogenic Therapy by Comparing the Gene Expressions of Tumor and Normal Endothelial Cells, Cancer Sci, 105(5), 560-567, 2014
  9. Habiba U., Kitamura T. Yanagawa-Matsuda A., Hida K., Higashino F., Ohiro Y., Totsuka Y. and Shindoh M.：Cytoplasmic expression of HuR may be a valuable diagnostic tool for determining the potential for malignant transformation of oral verrucous borderline lesions, Oncol Rep, 31(4), 1547-1554, 2014
  10. Sakurai Y., Hatakeyama H., Sato Y., Hyodo M., Akita H.,Ohga N., Hida K., Harashima H.：RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system, J Control Release, 173(10), 110-118, 2014